Stock Events

Stock Events

PhaseRx 

$0.000100
2
+$0.00+0% Thursday 20:00

Statistics

Day High
0.0002
Day Low
0.0002
52W High
0.0002
52W Low
0.0001
Volume
250
Avg. Volume
0
Mkt Cap
1,169
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

10NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2014
2015
2016
0Revenue
-20.14MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PZRXQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for genetic diseases, directly competing with PhaseRx's RNA-targeted treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals specializes in antisense technology, which is similar to PhaseRx's RNA-based drug development.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.83B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, similar to PhaseRx's approach.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics focuses on RNA-targeted drug discovery, particularly in areas like Duchenne muscular dystrophy, a potential area for PhaseRx.
Moderna
MRNA
Mkt Cap31.65B
Moderna Inc. is known for its work in mRNA therapies, which competes with PhaseRx's focus on RNA technologies.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical develops enzyme replacement therapies, which can be seen as alternative treatments to PhaseRx's genetic disorder therapies.
uniQure N.V.
QURE
Mkt Cap2.87B
uniQure is involved in gene therapy for genetic diseases, competing with PhaseRx's gene-focused therapeutic approaches.

About

PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells. The company's pipeline includes several programs targeting urea cycle disorders, such as PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency. Established in 2006, PhaseRx is headquartered in Seattle, Washington.
Show more...
CEO
Dr. Robert W. Overell Ph.D.
Employees
10
Country
United States
ISIN
US71723F1030

Listings

OTC Link
US
PZRXQ

0 Comments

Share your thoughts

FAQ

What is PhaseRx stock price today?▼
The current price of PZRXQ is $0.00 USD — it has increased by +0% in the past 24 hours. Watch PhaseRx stock price performance more closely on the chart.
What is PhaseRx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange PhaseRx stocks are traded under the ticker PZRXQ.
Is PhaseRx stock price growing?▼
PZRXQ stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year PhaseRx has showed a +0% increase.
What is PhaseRx market cap?▼
Today PhaseRx has the market capitalization of 1,169
What were PhaseRx earnings last quarter?▼
PZRXQ earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PhaseRx revenue for the last year?▼
PhaseRx revenue for the last year amounts to 0 USD.
What is PhaseRx net income for the last year?▼
PZRXQ net income for the last year is -20.14M USD.
How many employees does PhaseRx have?▼
As of July 11, 2026, the company has 10 employees.
In which sector is PhaseRx located?▼
PhaseRx operates in the Health & Wellness sector.
When did PhaseRx complete a stock split?▼
PhaseRx has not had any recent stock splits.
Where is PhaseRx headquartered?▼
PhaseRx is headquartered in Seattle, United States.